Health

Health conseil

Secteur Health Eurogroup Consulting

OVERALL VIEW

New public-health needs (an ageing population, an increase in chronic illnesses), the urgent need to control expenditure (T2A activity pricing, reduced hospitalisation), regional health policies supervised by regional health agencies, an enhanced role for patients (health democracy, quality of care and service supply) are among the main recent structural developments in France’s healthcare sector.

All families of operator – treatment producers, healthcare industries and agencies, supervisors and regulators – are confronted by these issues and must deal with them.

Treatment producers

The health system is made up of public establishments (hospitals) and private facilities that may or may not be part of the public hospital service (SPH).

French hospitals manage more than 250,000 patients each day and employ over a million staff. Their state-of-the-art services are globally renowned, but their A&E departments are often overloaded. There are CHUs (University Hospital Centres) or smaller local establishments. Shortages of staff and resources (especially in A&E) and concerns about a decline in the quality of care are often cited.

EPHADs (public establishments for the accommodation of dependent elderly persons) and palliative-care services are central to the reconfiguration of the medico-social sector. The aim is to organize management and coordination with other care producers on a local scale.

Local surgery practice is a factor in countering depopulation in certain regions. GPs can be seen as the first link in the healthcare chain. The 2009 HPST law (Hospital, Patient, Health, Regions) ensures continuity of treatment between hospitals, medico-social services and local GPs.

Healthcare networks – health workers cooperating on a voluntary basis in a given area – are to be developed and professionalised to more effectively meet the needs of populations.

Healthcare industries

Increases in development costs, longer clinical trials and a fall in the proportion of drugs marketed are all factors driving change in the business models of the pharmaceutical industry, especially given the emergence of new competition from generic-drug manufacturers and regulatory pressures.

Supervisory and regulatory agencies

Regional health agencies were intended to be the keystones of the French system (the HPST law), but are struggling at present, mainly because of supervisory decisions that are incompatible with their task (excessively broad objectives, lack of recognition) and difficulties in cooperating with health-insurance bodies. HR, financial and IS resources must be deployed to modernise these regional health agencies.

L'offre Eurogroup Consulting - Health Eurogroup Consulting

YOUR CONCERNS

Care producers: the modernisation objective

- Planning, configuring and directing strategic plans
- Service offer
- Facilitating the patient itinerary
- Mobilizing staff / supporting change
- Optimising support functions
- Reconfiguring the HR function as a lever for performance
- Aligning hospital information systems to reflect strategic choices

Agencies, supervisors and regulators: the optimisation objective

- Planning, configuring and directing strategic plans
- Developing standard tools for health agencies
- Modernising information systems

Private / public sources of funds for the supply of treatment: the equilibrium objective

- Managing mergers of mutual funds and joint bodies 
- Developing commercial networks and strategies
- Designing policy and strategy projects
- Conducting organizational optimisation audits and assignments

Healthcare industries: the innovation objective

- Developing managerial culture
- Conducting market and innovation research
- Optimising logistics / the supply chain
- Reorganizing the IS function

Experts
Health Eurogroup Consulting